Author:
Wanji Samuel,Chunda Valerine Chawa,Fombad Fanny Fri,Njouendou Abdel Jélil,Gandjui Narcisse Victor T.,Ritter Manuel,Enyong Peter A.,Mackenzie Charles,Taylor Mark J.,Hoerauf Achim,Turner Joseph D.
Abstract
The tropical disease, loiasis, caused by the filarial parasite, Loa loa, has gained prominence in global public health as a cause of excess mortality and a barrier to the elimination of the related prioritized neglected tropical diseases (NTDs), lymphatic filariasis and onchocerciasis, within Central Africa. There are no effective drug cures or vaccines available to treat loiasis safely. Here we review recent advances in loiasis preclinical platform technologies, including novel in vitro culturing systems, animal models and innovations in experimental infections of the L. loa vector, Chrysops, that have facilitated access to all L. loa filarial life-cycle stages. We detail applications of these new model systems in anti-filarial drug screening, diagnostic development, immunology, and pathophysiology research. Finally, we provide an overview of how loiasis preclinical platforms may be further utilized in translational medicine applications to support the development of much needed new interventions against filarial NTDs.
Funder
Bill and Melinda Gates Foundation
Deutsche Forschungsgemeinschaft
Wellcome Trust
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献